30 closest matches · ranked by relevance
Non-24-Hour Sleep-Wake Disorder
Primary: Proportion of Patients Entrained as Assessed by Urinary aMT6 — 20; 2.6 percentage of patients
Non-24-Hour Sleep-Wake Disorder
Primary: Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD. — 9; 2 participants
Delayed Sleep Phase Syndrome
Primary: Change From Baseline Time of Dim Light Melatonin Onset (DLMO) at 4 Weeks — -1.23; -1.58 Hours — p=0.510
Sleep Initiation and Maintenance Disorders
Primary: Total Sleep Time — 393; 420; 398; 409 units on a scale (minutes)
Sleep Disorders
Primary: Dim Light Melatonin Onset (Hours) — 1.93; 0.80 hours
Shift-Work Related Sleep Disturbance
Primary: Daytime Total Sleep Time in Minutes Per Day Collected From the Consensus Sleep Diary — 362.7; 365.3 Minutes per day — p=0.884
Non-24-Hour-Sleep-Wake Disorder
Primary: Absolute Bioavailability After a Single Oral Dose of Hetlioz™(Tasimelteon) 20mg — 38.3 Geometric Mean Ratio (%)
Delayed Sleep-Wake Phase Disorder
Primary: Change in School Night Sleep Onset Time — 0.4; 0.6 hours
Renal Disease · Sleep Disorders
Primary: Bedtime — 7.44; 7.24; 22.98; 22.48 Hours
Glucose Intolerance · Sleep Deprivation · Sleep
Primary: Impairment of Insulin Sensitivity — -0.80; 0.55 (mU/L)^-1 min^-1
Delayed Sleep Phase
Primary: Weekday Sleep Duration - Actigraphy — 6.309; 5.866; 5.880; 5.845 Number of hours — p=0.018
Sleep Disturbances
Primary: Sleep Disturbance — -1.9; -1.3 units on a scale
Night Eating Syndrome
Primary: Night Eating Questionnaire — -13.0; -10.6 units on a scale
Delayed Sleep Phase Syndrome
Primary: To Investigate the Efficacy on Rise Time of Bright Light Therapy and Melatonin Treatment Using a 4 Armed Placebo Controlled Design. Main Outcome Measures: Sleep Log…
Insomnia Disorder
Primary: Sleep Efficiency — 95.1 percent
Non-Diabetic Disorder of Endocrine Pancreas
Primary: Area Under the Curve (AUC) Glucose — 278.84; 268.92; 260.66; 282.21 mg*h/dL
Obstructive Sleep Apnea
Primary: Feasibility of Recruitment and Retention — 8; 6; 8; 6 participants
Shift-Work Sleep Disorder
Primary: Nighttime Wakefulness Assessed by Mean Sleep Latency Across 4 Maintenance of Wakefulness Tests — 11.0; 14.75 minutes
Mental Disorders
Primary: Impairment (Sheehan Disability Scale) — 14.30; 12.03; 11.76; 6.57 score on a scale — p=0.025
Sleep Disorder, Shift-Work
Primary: Change in Average Total Sleep Time — 1.83; -0.33 hours/sleep opportunity — p=<0.05
Insomnia · Sleep
Primary: Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total Score — 72.64 units on a scale
Jet Lag Disorder
Primary: Total Sleep Time in the First Two-Thirds of the Night on the Night(s) Most Likely to be Disrupted — 76.2; 41.4 minutes — p=0.0354
Sleep Phase Rhythm Disturbance · Sleep Deprivation
Primary: 17-Item Hamilton Rating Scale for Depression Score (Independent Evaluator) — 8.66; 10.46 units on a scale
Sleep Disorders, Circadian Rhythm
Primary: Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 6-7) — 59.30; 39.40; 55.94; 55.12 minutes — p=0.646
Irregular Sleep-Wake Rhythm Disorder
Primary: Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of Treatment — 76.34; 77.64; 78.45; 76.38…
Seasonal Affective Disorder
Primary: Sleep Satisfaction at Baseline and Measured Monthly, as Measured by the Pittsburgh Sleep Quality Index (PSQI) — 11.56; 11.45; 9.52; 8.67 scores on a scale
Nocturia · Daytime Sleepiness
Primary: Change From Baseline in Epworth Sleepiness Scale [ESS] — 9.03; 9.73 units on a scale
Narcolepsy · Sleep Apnea, Obstructive · Sleep Apnea Syndromes
Primary: Safety and Tolerability as Measured by Number of Participants With Adverse Events — 323 Participants
Sleep Deprivation · Diabetes · Circadian Dysregulation
Primary: Oral Disposition Index — 11.5 None (Index) — p=.13
Non-visual Photoreception
Primary: Melatonin Suppression — 71.4; 70.1; 54.3; 32.5 Percentage suppression — p=0.73